Vanda Pharmaceuticals is a global biopharmaceutical company that is dedicated to developing and commercializing innovative therapies to address the high unmet medical needs of patients. They are committed to improving lives and use cutting-edge technologies, such as genetics and genomics, to inform their drug discovery, clinical trials, and commercial positioning of their compounds. Founded in 2003 by CEO Mihael Polymeropoulos, MD, in partnership with Care Capital LLC and Bio*One Capital, Vanda has a strong focus on new biomedical enterprises.

They have a diverse and experienced team of corporate officers and board members who work together to achieve their common goal. Over the years, Vanda has made significant advancements in the development of therapeutics. They have successfully obtained FDA approvals for important drugs like Fanapt® for schizophrenia and Hetlioz® for Non24 Hour Sleep Wake Disorder.

They are also actively working on developing treatments for atopic dermatitis, gastroparesis, Smith Magenis Syndrome, Jet Lag Disorder, and hematologic malignancies. Vanda's commitment to improving patient outcomes is evident in their comprehensive compliance program and adherence to corporate governance guidelines. They are dedicated to delivering safe and effective treatments to patients worldwide